IP Library Granted Patent US 8,937,070
Granted Patent B2
US 8,937,070 · App. 13/916,926 · Granted Jan 20, 2015

Inhibitors of protein kinases

Inventors: Shawn M. Bauer (Pacifica, CA); Anjali Pandey (Fremont, CA)
Assignee: Portola Pharmaceuticals, Inc.
C07D401/12C07D239/48A61K31/5377C07D413/12C07D403/14C07D417/12C07D413/14A61K31/506C07D403/12A61K31/5355A61K31/505C07D401/14A61K31/551A61K31/4985
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,937,070
App. No.
13/916,926
Granted
Jan 20, 2015
Kind
B2
Abstract

The present invention is directed to methods of inhibiting syk and/or JAK kinase activity, methods of inhibiting platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma with compounds of the formula: and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof.

Claims (11)

1. A method for treating rheumatoid arthritis or Non Hodgkin's Lymphoma in a subject comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound having the formula:

wherein D 1 is C 3-8 cycloalkyl, or a pharmaceutically acceptable tautomer, salt, or stereoisomer thereof.

2. The method of claim 1 , wherein the compound has the formula:

or a pharmaceutically acceptable tautomer, salt, or stereoisomer thereof.

3. A method of claim 2 , wherein D 1 is cyclopropyl or cyclobutyl.

4. A method of claim 2 , wherein D 1 is cyclopropyl.

5. A method of claim 2 , wherein D 1 is cyclobutyl.

6. A method of claim 2 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof.

7. A method of claim 2 , wherein the compound has the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054999/0218 →
CHANGE OF NAME Recorded Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054975/0183 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
SECURITY INTEREST Recorded Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2015
From: BAUER, SHAWN M.; JIA, ZHAOZHONG J.; SONG, YONGHONG; XU, QING; MEHROTRA, MUKUND; ROSE, JACK W.; HUANG, WOLIN; VENKATARAMANI, CHANDRASEKAR; PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 035405/0842 →
Continuity (11)
Continuation 13360862 · Jan 30, 2012
Continuation 12386509 · Apr 16, 2009
Provisional Application 61120348 · Dec 5, 2008
Provisional Application 61120346 · Dec 5, 2008
Provisional Application 61120344 · Dec 5, 2008
Provisional Application 61120341 · Dec 5, 2008
Provisional Application 61045499 · Apr 16, 2008
Provisional Application 61045417 · Apr 16, 2008
Provisional Application 61045406 · Apr 16, 2008
Provisional Application 61045399 · Apr 16, 2008
Related Publication 20140031361A1 · Jan 30, 2014